CN105188687B - Metadichol*液体和凝胶纳米颗粒制剂 - Google Patents
Metadichol*液体和凝胶纳米颗粒制剂 Download PDFInfo
- Publication number
- CN105188687B CN105188687B CN201480016205.7A CN201480016205A CN105188687B CN 105188687 B CN105188687 B CN 105188687B CN 201480016205 A CN201480016205 A CN 201480016205A CN 105188687 B CN105188687 B CN 105188687B
- Authority
- CN
- China
- Prior art keywords
- use according
- disease
- skin disease
- patients
- thyroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794490P | 2013-03-15 | 2013-03-15 | |
| US61/794,490 | 2013-03-15 | ||
| PCT/US2014/023777 WO2014150609A1 (en) | 2013-03-15 | 2014-03-11 | Metadichol r liquid and gel nanoparticle formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105188687A CN105188687A (zh) | 2015-12-23 |
| CN105188687B true CN105188687B (zh) | 2018-05-01 |
Family
ID=51530033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480016205.7A Active CN105188687B (zh) | 2013-03-15 | 2014-03-11 | Metadichol*液体和凝胶纳米颗粒制剂 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9006292B2 (https=) |
| EP (1) | EP2968209B1 (https=) |
| JP (2) | JP5996146B2 (https=) |
| KR (1) | KR101700949B1 (https=) |
| CN (1) | CN105188687B (https=) |
| AU (1) | AU2014235779B2 (https=) |
| BR (1) | BR112015011379B1 (https=) |
| CA (1) | CA2894370C (https=) |
| DK (1) | DK2968209T3 (https=) |
| HK (1) | HK1212247A1 (https=) |
| MX (1) | MX359686B (https=) |
| RU (2) | RU2631600C2 (https=) |
| SG (1) | SG11201506430XA (https=) |
| WO (1) | WO2014150609A1 (https=) |
| ZA (1) | ZA201505436B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| HUE069400T2 (hu) * | 2019-09-30 | 2025-03-28 | Tolmar International Ltd | Folyékony polimer készítmények és rendszerek peptidek mint hatóanyagok nyújtott leadására |
| US11554087B2 (en) | 2020-11-05 | 2023-01-17 | The Gillette Company Llc | Shaving aid comprising an antioxidant |
| CN114699537B (zh) * | 2022-03-07 | 2024-06-21 | 西安交通大学医学院第一附属医院 | 一种改善缺氧增敏pd-1抗体疗效的ros响应抗癌药物 |
| EP4618972A1 (en) * | 2022-11-18 | 2025-09-24 | Phytoceutical Limited | Biofilm treatment |
| CN118011012B (zh) * | 2024-02-19 | 2025-01-21 | 中国科学院昆明动物研究所 | LL-37-ApoB-100生物标志物及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030198616A1 (en) * | 2002-04-23 | 2003-10-23 | Combe Incorporated | Moisturizing skin gel and method |
| US20070196507A1 (en) * | 2003-07-01 | 2007-08-23 | Muhammed Majeed | Compositions and methods containing high purity fatty alcohol C24 to C36 for cosmetic applications |
| CN102292088A (zh) * | 2009-02-23 | 2011-12-21 | 奈米瑞斯公司 | 普利醇纳米粒子 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670471A (en) * | 1981-11-03 | 1987-06-02 | Clark Lealand L | Treatment for inflammatory skin disease |
| US20090191288A1 (en) | 1996-02-12 | 2009-07-30 | Squires Meryl J | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases |
| JP4533134B2 (ja) * | 2002-06-10 | 2010-09-01 | エラン ファーマ インターナショナル，リミティド | ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ |
| ITMI20031313A1 (it) * | 2003-06-27 | 2004-12-28 | Indena Spa | Associazioni di agenti vasoprotettori e formulazioni che li contengono. |
| US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
| WO2008070602A2 (en) * | 2006-12-04 | 2008-06-12 | Smithkline Beecham Corporation | Topical pharmaceutical composition |
| WO2011064631A1 (en) * | 2009-10-02 | 2011-06-03 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
| WO2012027159A1 (en) * | 2010-08-23 | 2012-03-01 | NanoRx, Inc. | Policosanol nanoparticles |
| US20130045179A1 (en) | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
-
2014
- 2014-03-11 KR KR1020157020035A patent/KR101700949B1/ko active Active
- 2014-03-11 US US14/205,243 patent/US9006292B2/en active Active
- 2014-03-11 JP JP2016501340A patent/JP5996146B2/ja active Active
- 2014-03-11 CN CN201480016205.7A patent/CN105188687B/zh active Active
- 2014-03-11 BR BR112015011379-6A patent/BR112015011379B1/pt active IP Right Grant
- 2014-03-11 SG SG11201506430XA patent/SG11201506430XA/en unknown
- 2014-03-11 RU RU2015143270A patent/RU2631600C2/ru active
- 2014-03-11 DK DK14770019.9T patent/DK2968209T3/da active
- 2014-03-11 EP EP14770019.9A patent/EP2968209B1/en active Active
- 2014-03-11 RU RU2017116682A patent/RU2736752C2/ru active
- 2014-03-11 MX MX2015008676A patent/MX359686B/es active IP Right Grant
- 2014-03-11 AU AU2014235779A patent/AU2014235779B2/en active Active
- 2014-03-11 WO PCT/US2014/023777 patent/WO2014150609A1/en not_active Ceased
- 2014-03-11 HK HK16100350.6A patent/HK1212247A1/xx unknown
- 2014-03-11 CA CA2894370A patent/CA2894370C/en active Active
-
2015
- 2015-07-28 ZA ZA2015/05436A patent/ZA201505436B/en unknown
-
2016
- 2016-07-12 JP JP2016137526A patent/JP6346918B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030198616A1 (en) * | 2002-04-23 | 2003-10-23 | Combe Incorporated | Moisturizing skin gel and method |
| US20070196507A1 (en) * | 2003-07-01 | 2007-08-23 | Muhammed Majeed | Compositions and methods containing high purity fatty alcohol C24 to C36 for cosmetic applications |
| CN102292088A (zh) * | 2009-02-23 | 2011-12-21 | 奈米瑞斯公司 | 普利醇纳米粒子 |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201506430XA (en) | 2015-09-29 |
| AU2014235779B2 (en) | 2015-11-26 |
| JP2017008057A (ja) | 2017-01-12 |
| EP2968209A4 (en) | 2016-11-02 |
| MX2015008676A (es) | 2016-04-25 |
| RU2015143270A (ru) | 2017-04-27 |
| RU2017116682A (ru) | 2018-10-23 |
| KR20150127575A (ko) | 2015-11-17 |
| US9006292B2 (en) | 2015-04-14 |
| CA2894370C (en) | 2016-01-12 |
| EP2968209B1 (en) | 2020-12-16 |
| JP5996146B2 (ja) | 2016-09-21 |
| RU2017116682A3 (https=) | 2020-06-03 |
| JP2016512827A (ja) | 2016-05-09 |
| CA2894370A1 (en) | 2014-09-25 |
| BR112015011379B1 (pt) | 2022-10-11 |
| JP6346918B2 (ja) | 2018-06-20 |
| WO2014150609A1 (en) | 2014-09-25 |
| AU2014235779A1 (en) | 2015-09-03 |
| ZA201505436B (en) | 2016-07-27 |
| RU2736752C2 (ru) | 2020-11-19 |
| MX359686B (es) | 2018-10-05 |
| RU2631600C2 (ru) | 2017-09-25 |
| HK1212247A1 (en) | 2016-06-10 |
| CN105188687A (zh) | 2015-12-23 |
| DK2968209T3 (da) | 2021-01-04 |
| EP2968209A1 (en) | 2016-01-20 |
| BR112015011379A2 (https=) | 2017-08-22 |
| US20140275285A1 (en) | 2014-09-18 |
| KR101700949B1 (ko) | 2017-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105188687B (zh) | Metadichol*液体和凝胶纳米颗粒制剂 | |
| Wu et al. | Turmeric‐derived nanoparticles functionalized aerogel regulates multicellular networks to promote diabetic wound healing | |
| Kamar et al. | Beneficial effect of Curcumin Nanoparticles-Hydrogel on excisional skin wound healing in type-I diabetic rat: Histological and immunohistochemical studies | |
| Zhuo et al. | Targeted modulation of intestinal epithelial regeneration and immune response in ulcerative colitis using dual-targeting bilirubin nanoparticles | |
| Lu et al. | Mesenchymal stem cell-derived extracellular vesicles accelerate diabetic wound healing by inhibiting NET-induced ferroptosis of endothelial cells | |
| Shamshiri et al. | Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: In vitro and in vivo studies in a colon cancer mouse model | |
| Zhang et al. | A “bulldozer” driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy | |
| de Lima Nunes et al. | Curzerene antileishmania activity: Effects on Leishmania amazonensis and possible action mechanisms | |
| Zhao et al. | Targeting synovial macrophages with astaxanthin-loaded liposomes for antioxidant treatment of osteoarthritis | |
| WO2025054501A1 (en) | Modified silk fibroin and medical uses thereof | |
| Tian et al. | Injectable thermosensitive selenium-containing hydrogel as mesenchymal stem cell carrier to improve treatment efficiency in limb ischemia | |
| AU2020202785B2 (en) | Formulation for use in the treatment of uremic pruritus | |
| Liu et al. | Regulation of sheep α-TTP by dietary vitamin E and preparation of monoclonal antibody for sheep α-TTP | |
| Chen et al. | Break the vicious cycle and remodel the malignant inflammatory microenvironment in ARDS with efferocytosis-informed nanodrugs | |
| JP2022064275A (ja) | 上皮細胞がんを治療する医薬組成物を調製するための小胞子霊芝の免疫調節タンパク質及びキーホールリンペットヘモシアニン及びその用途 | |
| Du et al. | Chromobox protein homolog 7 (CBX7) deficiency inhibits osteoblast ferroptosis by activating the Nrf2 function in type 2 diabetic osteoporosis | |
| US20180133148A1 (en) | Degradable Microparticles for Protein and Small Molecule Delivery | |
| Abbasi-Malati et al. | Autophagy stimulation influenced the angiogenesis and metastasis behavior of human triple-negative breast cancer cells | |
| Liu et al. | Hyaluronic acid-based ROS-responsive nanomicelles for curcumin delivery in the treatment of LPS-induced acute kidney injury | |
| Wu et al. | Effects of anti-PEG antibodies on extravascular transport of stealth liposome: A study on interspecies difference | |
| Wu et al. | Microenvironment-educated MSC-EVs loaded injectable smart hydrogel for targeting senescent nucleus pulposus cells and inhibiting ferroptosis against intervertebral disc degeneration | |
| Goncalves | Peripheral Neuroinflammation and Novel Potential Therapeutic Targets in Familial Amyloidotic Polyneuropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1212247 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1212247 Country of ref document: HK |